AMICUS THERAPEUTICS, INC. — Director's Dealing 2022

Jan 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-12-31

Reporting Person: Rosenberg Ellen (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-31	Common Stock	F	9483	$11.55	Disposed	231723	Direct
2022-01-02	Common Stock	F	6589	$11.55	Disposed	225134	Direct
2022-01-03	Common Stock	F	2970	$12.11	Disposed	222164	Direct
2022-01-03	Common Stock	A	73136	—	Acquired	295300	Direct
2022-01-04	Common Stock	F	3575	$12.48	Disposed	291725	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-03	Stock Options (right to buy)	$12.11	A	134044	Acquired	2032-01-03	Common Stock (134044)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15000	Indirect

Footnotes

F1: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.

F2: The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023.

F3: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.